Ireland· IE-PA-EU/1/15/1057/004-006
Pemetrexed Pfizer 25 mg/ml concentrate for solution for infusion
A pemetrexed product containing pemetrexed disodium hemipentahydrate + pemetrexed, registered in Ireland by Pfizer Europe MA EEIG. The same ATC class is registered in 17 of our 19 countries.
Checked against HPRA (Ireland) on
Informational only — not a medical device.
Where it is registered
Pemetrexed is registered in 17 of 19 countries.
Countries holding a registration under ATC L01BA04 (pemetrexed), each read from that country’s own register.
- This record: Ireland, from HPRA (Ireland)
- 10 of them publish a price we can compare per daily dose
Pemetrexed · ATC L01BA04
17 / 19 countries
- Belgiumprice
- Canada
- Czechiaprice
- Denmark
- Finlandprice
- Franceprice
- Germany
- Icelandprice
- Ireland
- Netherlands
- Norwayprice
- Polandprice
- Spainprice
- Sweden
- Switzerlandprice
- United Kingdom
- United Statesprice
Price per daily dose
What a daily dose of pemetrexed costs, country by country.
Normalised to the WHO defined daily dose (43 mg), so markets compare like for like.
- 1 market with a comparable price for this class
- Public list prices, converted to USD at the rate date shown
Pemetrexed · price per daily dose (43 mg)
USD · FX 28 Sept 2026
- CH Switzerland$49.69
The record
At a glance
HPRA (Ireland)- Active substance
- Pemetrexed Disodium Hemipentahydrate + Pemetrexed
- Manufacturer
- Pfizer Europe MA EEIG
- Country
- Ireland (IE)
- ATC code
- L01BA04
- ATC class
- Pemetrexed
- Defined daily dose
- 43 mg, P
- Reimbursed
- Not published by this register
- Source register
- HPRA (Ireland)
- Last checked
- September 28, 2026
Packs & prices · 1
- ie_pa_numberEU/1/15/1057/004-006
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Interactions
387 interactions on record for pemetrexed.
Graded by severity as the source publishes them — 30 severe. Severity grades are free for everyone; mechanism and management come with Growth.
- Severity for every pair — free, no plan needed
- The source, licence and sync date on every record
- Mechanism and what to do for each pair — Growth plan
Pemetrexed · interactions on record
387 records
- 30 severe
- 240 moderate
- 117 info
Most severe, free to view
- CladribineL01BB04severe
- Talimogene laherparepvecL01XL02severe
- CimetidineA02BA01moderate
- RanitidineA02BA02moderate
- Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Same class
Other records under L01BA04
Pemetrexed, as other registers publish it.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of HPRA (Ireland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/e4060f65-b3a6-4009-a74f-2429d98ec689 GET /v1/drugs/e4060f65-b3a6-4009-a74f-2429d98ec689?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"form": "Concentrate for solution for infusion",
"routes": [
"Intravenous use"
],
"source": "hpra",
"atc_all": [
"L01BA04"
],
"strength": null,
"pa_number": "EU/1/15/1057/004-006",
"substances": [
"Pemetrexed Disodium Hemipentahydrate",
"Pemetrexed"
],
"legal_basis": "Hybrid application (Article 10(3) of Directive No 2001/83/EC)",
"market_info": "Unknown",
"authorised_at": "30/09/2020",
"dispensing_status": "Product subject to prescription which may not be renewed (A)",
"registration_status": "AU",
"supply_legal_status": "Supply through pharmacies only",
"interchangeable_code": null
}See everything about pemetrexed.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.